BRCA1/2突变乳腺癌临床诊治新进展—机遇和挑战

万琪婷 孙洁 胡丽 解云涛

万琪婷, 孙洁, 胡丽, 解云涛. BRCA1/2突变乳腺癌临床诊治新进展—机遇和挑战[J]. 中国肿瘤临床, 2022, 49(23): 1189-1195. doi: 10.12354/j.issn.1000-8179.2022.20221292
引用本文: 万琪婷, 孙洁, 胡丽, 解云涛. BRCA1/2突变乳腺癌临床诊治新进展—机遇和挑战[J]. 中国肿瘤临床, 2022, 49(23): 1189-1195. doi: 10.12354/j.issn.1000-8179.2022.20221292
Qiting Wan, Jie Sun, Li Hu, Yuntao Xie. Progress of clinical management in patients with breast cancer carrying BRCA1/2 germline pathogenic mutations — opportunities and challenges[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 49(23): 1189-1195. doi: 10.12354/j.issn.1000-8179.2022.20221292
Citation: Qiting Wan, Jie Sun, Li Hu, Yuntao Xie. Progress of clinical management in patients with breast cancer carrying BRCA1/2 germline pathogenic mutations — opportunities and challenges[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 49(23): 1189-1195. doi: 10.12354/j.issn.1000-8179.2022.20221292

BRCA1/2突变乳腺癌临床诊治新进展—机遇和挑战

doi: 10.12354/j.issn.1000-8179.2022.20221292
基金项目: 本文课题受国家自然科学基金项目(编号:81772824、81802635)资助
详细信息
    作者简介:

    万琪婷:专业方向为乳腺癌易感基因的相关研究

    通讯作者:

    解云涛 zlxyt2@bjmu.edu.cn

Progress of clinical management in patients with breast cancer carrying BRCA1/2 germline pathogenic mutations — opportunities and challenges

Funds: This work was supported by the National Natural Science Foundation of China (No. 81772824, No. 81802635)
More Information
  • 摘要: BRCA1/2胚系突乳腺癌具有特殊的发病机制及临床病理特征,其临床决策有别于散发性乳腺癌。随着基因测序技术的发展,越来越多的BRCA1/2突变乳腺癌被检测出。BRCA1/2突变乳腺癌的相关临床管理越来越得到重视。本文总结近年来的相关文献,对BRCA1/2突变乳腺癌患者的基因检测和手术、化疗、靶向治疗等诊疗进展进行综述,以期为BRCA1/2突变患者的临床决策提供帮助。

     

  • [1] Zang F, Ding X, Chen J, et al. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype[J]. Breast Cancer Res Treat, 2022, 195(3):431-439. doi: 10.1007/s10549-022-06702-4
    [2] Deng M, Chen HH, Zhu X, et al. Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2, 769 unselected breast cancer patients in China[J]. Int J Cancer, 2019, 145(6):1517-1528. doi: 10.1002/ijc.32184
    [3] Bhaskaran SP, Chandratre K, Gupta H, et al. Germline variation in BRCA1/2 is highly ethnic-specific: Evidence from over 30, 000 Chinese hereditary breast and ovarian cancer patients[J]. Int J Cancer, 2019, 145(4):962-973. doi: 10.1002/ijc.32176
    [4] Meng H, Yao L, Yuan H, et al. BRCA1 c. 5470_5477del, a founder mutation in Chinese Han breast cancer patients[J]. Int J Cancer, 2020, 146(11):3044-3052. doi: 10.1002/ijc.32877
    [5] Yao L, Sun J, Zhang J, et al. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations[J]. Breast Cancer Res Treat, 2016, 156(3):441-445. doi: 10.1007/s10549-016-3766-3
    [6] Fu F, Zhang D, Hu L, et al. Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women[J]. Cancer Biol Med, 2021:253-262.
    [7] Yao L, Sun J, Hu L, et al. Ovarian cancer risk of Chinese women with BRCA1/2 germline pathogenic variants[J]. J Hum Genet, 2022, 67(11):639-642. doi: 10.1038/s10038-022-01065-6
    [8] Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage Ⅰ/Ⅱ breast cancer[J]. J Clin Oncol, 2006, 24(16):2437-2443. doi: 10.1200/JCO.2005.02.7888
    [9] Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases[J]. Eur J Cancer, 2007, 43(5):867-876. doi: 10.1016/j.ejca.2006.12.009
    [10] Garcia-Etienne CA, Barile M, Gentilini OD, et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer[J]. Ann Surg Oncol, 2009, 16(12):3380-3387. doi: 10.1245/s10434-009-0638-7
    [11] Kirova YM, Savignoni A, Sigal-Zafrani B, et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature [J]. Breast Cancer Res Treat, 2010, 120(1):119-126.
    [12] Cao W, Xie Y, He Y, et al. Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China[J]. Breast Cancer Res Treat, 2019, 175(3):749-754. doi: 10.1007/s10549-019-05199-8
    [13] Wan Q, Su L, Ouyang T, et al. Comparison of survival after breast-conserving therapy vs mastectomy among patients with or without the BRCA1/2 variant in a large series of unselected Chinese patients with breast cancer[J]. JAMA Netw Open, 2021, 4(4):e216259.
    [14] Kirova YM, Stoppa-Lyonnet D, Savignoni A, et al. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy[J]. Eur J Cancer, 2005, 41(15):2304-2311. doi: 10.1016/j.ejca.2005.02.037
    [15] Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy[J]. Breast Cancer Res Treat, 2010, 121(2):389-398. doi: 10.1007/s10549-010-0894-z
    [16] Nilsson MP, Hartman L, Kristoffersson U, et al. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer[J]. Breast Cancer Res Treat, 2014, 147(3):571-578.
    [17] van den Broek AJ, Schmidt MK, van 't Veer L J, et al. Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients [J]. Ann Surg, 2019, 270(2):364-372.
    [18] Tung NM, Boughey JC, Pierce LJ, et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline[J]. J Clin Oncol, 2020, 38(18):2080-2106. doi: 10.1200/JCO.20.00299
    [19] Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA, 2017, 317(23):2402-2416. doi: 10.1001/jama.2017.7112
    [20] Su L, Xu Y, Ouyang T, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients[J]. Int J Cancer, 2020, 146(12):3335-3342.
    [21] van den Broek AJ, van 't Veer LJ, Hooning MJ, et al. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers[J]. J Clin Oncol, 2016, 34(5):409-418. doi: 10.1200/JCO.2015.62.3942
    [22] Grobmyer SR, Pederson HJ, Valente SA, et al. Evolving indications and long-term oncological outcomes of risk-reducing bilateral nipple-sparing mastectomy[J]. BJS Open, 2019, 3(2):169-173. doi: 10.1002/bjs5.50117
    [23] Yao K, Liederbach E, Tang R, et al. Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature[J]. Ann Surg Oncol, 2015, 22(2):370-376. doi: 10.1245/s10434-014-3883-3
    [24] Semple J, Metcalfe KA, Lynch HT, et al. International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers[J]. Ann Surg Oncol, 2013, 20(12):3817-3822. doi: 10.1245/s10434-013-3040-4
    [25] Boughey JC, Hoskin TL, Hartmann LC, et al. Impact of reconstruction and reoperation on long-term patient-reported satisfaction after contralateral prophylactic mastectomy[J]. Ann Surg Oncol, 2015, 22(2):401-408. doi: 10.1245/s10434-014-4053-3
    [26] Tutt A, Tovey H, Cheang MU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial[J]. Nat Med, 2018, 24(5):628-637. doi: 10.1038/s41591-018-0009-7
    [27] Jacot W, Lusque A, Vicier C, et al. Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations [J]. Br J Cancer, 2022,doi: 10.1038/s41416-022-02003-1.
    [28] Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients[J]. Breast Cancer Res Treat, 2014, 147(2):401-405. doi: 10.1007/s10549-014-3100-x
    [29] Byrski T, Gronwald J, Huzarski T, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy[J]. J Clin Oncol, 2010, 28(3):375-379. doi: 10.1200/JCO.2008.20.7019
    [30] Zhang J, Yao L, Liu Y, et al. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer[J]. Int J Cancer, 2021, 148(4):941-949. doi: 10.1002/ijc.33234
    [31] Hahnen E, Lederer B, Hauke J, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial[J]. JAMA Oncol, 2017, 3(10):1378-1385. doi: 10.1001/jamaoncol.2017.1007
    [32] Andre F, Filleron T, Kamal M, et al. Genomics to select treatment for patients with metastatic breast cancer[J]. Nature, 2022, 610(7931):343-348. doi: 10.1038/s41586-022-05068-3
    [33] Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer[J]. N Engl J Med, 2021, 384(25):2394-2405. doi: 10.1056/NEJMoa2105215
    [34] Tung NM, Zakalik D, Somerfield MR, et al. Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update[J]. J Clin Oncol, 2021, 39(26):2959-2961. doi: 10.1200/JCO.21.01532
    [35] Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant[J]. J Clin Oncol, 2020, 38(5):388-394. doi: 10.1200/JCO.19.01304
    [36] Litton JK, Beck JT, Jones JM, et al. Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study[J]. J Clin Oncol, 2021, 39(15_Suppl):505. doi: 10.1200/JCO.2021.39.15_suppl.505
    [37] Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models[J]. Clin Cancer Res, 2007, 13(9):2728-2737. doi: 10.1158/1078-0432.CCR-06-3039
    [38] Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer[J]. N Engl J Med, 2016, 375(1):23-34. doi: 10.1056/NEJMoa1513749
    [39] Loibl S, O'Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(4):497-509.
    [40] Tung NM, Robson ME, Ventz S, et al. TBCRC 048: Phase Ⅱ study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes[J]. J Clin Oncol, 2020, 38(36):4274-4282. doi: 10.1200/JCO.20.02151
    [41] Blum JL, Laird AD, Litton JK, et al. Determinants of response to talazoparib in patients with HER2-negative, germline BRCA1/2-mutated breast cancer[J]. Clin Cancer Res, 2022, 28(7):1383-1390. doi: 10.1158/1078-0432.CCR-21-2080
    [42] Dias MP, Moser SC, Ganesan S, et al. Understanding and overcoming resistance to PARP inhibitors in cancer therapy[J]. Nat Rev Clin Oncol, 2021, 18(12):773-791. doi: 10.1038/s41571-021-00532-x
    [43] Nolan E, Savas P, Policheni AN, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer[J]. Sci Transl Med, 2017, 9(393):eaal4922. doi: 10.1126/scitranslmed.aal4922
    [44] Solinas C, Marcoux D, Garaud S, et al. BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer[J]. Cancer Lett, 2019, 450:88-97. doi: 10.1016/j.canlet.2019.02.027
  • 加载中
计量
  • 文章访问数:  342
  • HTML全文浏览量:  115
  • PDF下载量:  158
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-09-09
  • 录用日期:  2022-11-08
  • 修回日期:  2022-10-11
  • 网络出版日期:  2022-12-02

目录

    /

    返回文章
    返回